Does Blue Cross Blue Shield of Illinois Cover Novolog?

BCBSIL Formulary Placement for Novolog

Blue Cross Blue Shield of Illinois includes Novolog on the formularies of its major commercial, PPO, HMO, and ACA marketplace plans. The exact tier depends on your plan's benefit design. On many BCBSIL Blue Choice and Blue Advantage plans, Novolog sits at Tier 2 (preferred brand), which carries a lower copay than Tier 3. Other plan configurations slot it at Tier 3 (non-preferred brand), especially when BCBSIL has negotiated a deeper rebate on a competing rapid-acting analog like Humalog (insulin lispro) or the authorized generic insulin lispro.

You can verify your plan's current formulary placement by logging into the BCBSIL member portal or calling the number on the back of your insurance card. Formularies update at least annually, and mid-year changes can shift a drug between tiers. The American Diabetes Association (ADA) 2024 Standards of Care emphasize that cost should be an explicit factor in insulin selection, noting that "weights of patient preferences, cost, and ease of use should be considered" when choosing an insulin regimen 1. BCBSIL's formulary committee follows a similar logic: the plan's preferred product is typically the one with the best net cost after manufacturer rebates.

For employer-sponsored plans administered by BCBSIL, the employer selects the formulary tier structure. Self-funded employer plans may use a custom formulary that differs from the standard BCBSIL drug list. If your employer's plan excludes Novolog, your prescriber can request a formulary exception by documenting medical necessity.

What Novolog Costs Under BCBSIL Plans

Out-of-pocket costs for Novolog depend on three variables: your plan's tier, your copay or coinsurance structure, and whether you have met your deductible. On a typical BCBSIL commercial PPO plan with Novolog at Tier 2, copays range from $30 to $60 per 30-day supply after the deductible. At Tier 3, that range often climbs to $60 to $90. Plans that use coinsurance instead of flat copays may charge 25% to 40% of the negotiated price.

The list price of Novolog is roughly $290 per 10 mL vial, though the net price after rebates is substantially lower 2. High-deductible health plans (HDHPs) require you to pay the full negotiated rate until you clear your deductible, which can mean $150 to $250 per vial at the pharmacy counter in early months of the plan year.

Two cost-cap laws provide hard ceilings:

Illinois SB 667 (effective January 1, 2021). This state law caps cost-sharing for prescription insulin at $100 per 30-day supply for plans regulated by the Illinois Department of Insurance 3. It applies to most fully insured individual and small-group plans issued in Illinois but does not apply to self-funded employer plans governed by federal ERISA law.

Inflation Reduction Act (effective January 1, 2023). For Medicare Part D enrollees, out-of-pocket insulin costs are capped at $35 per month per covered insulin product 4. This applies regardless of whether you have reached your deductible.

If your monthly cost exceeds these caps, ask your pharmacist to reprocess the claim or contact BCBSIL member services to confirm the cap is being applied correctly.

Prior Authorization and Step Therapy Rules

Most BCBSIL commercial plans do not require prior authorization (PA) for Novolog when the prescriber writes a standard insulin aspart prescription for a patient with a documented diabetes diagnosis. This is consistent with ADA guidance that rapid-acting insulin analogs should be accessible without unnecessary administrative delays for patients with Type 1 diabetes, who have an absolute physiologic requirement for mealtime insulin 1.

Some plan designs, however, apply step therapy. Step therapy means BCBSIL requires you to try the plan's preferred rapid-acting insulin first (often Humalog or Admelog) before covering Novolog. If your prescriber believes Novolog is medically necessary over the preferred product, they can file a step-therapy exception. Valid clinical reasons include a documented adverse reaction to the preferred insulin, better postprandial glucose control on Novolog, or use of a Novolog-specific delivery device like the Novolog FlexPen.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the ADA, has stated: "No person with diabetes should ever have to ration their insulin because of cost or access barriers" 5. If you receive a PA denial, you have the right to appeal. BCBSIL must process urgent appeals within 72 hours.

Clinical Profile of Novolog (Insulin Aspart)

Novolog is a rapid-acting insulin analog approved by the FDA in 2000 for glycemic control in adults and children with Type 1 and Type 2 diabetes 6. Its onset of action is 10 to 20 minutes after subcutaneous injection, peak activity occurs at 1 to 3 hours, and total duration is 3 to 5 hours. This pharmacokinetic profile makes it well suited for mealtime bolus dosing.

The key trial comparing insulin aspart to regular human insulin in Type 1 diabetes (N=882) demonstrated that insulin aspart produced statistically superior 2-hour postprandial glucose control with no increase in severe hypoglycemia 7. A1C reductions were comparable between groups (approximately 0.15% difference, not statistically significant), confirming bioequivalence in overall glycemic control.

In Type 2 diabetes, the DECODE study framework and subsequent real-world analyses have shown that postprandial glucose excursions contribute significantly to cardiovascular risk, supporting the clinical rationale for rapid-acting analogs over regular human insulin 8. The Endocrine Society's 2022 clinical practice guideline on Type 2 diabetes management recommends rapid-acting analogs as the preferred mealtime insulin option when basal insulin alone is insufficient 9.

Novolog is also available as Novolog Mix 70/30, a premixed formulation containing 70% insulin aspart protamine and 30% insulin aspart. This premix is a separate formulary line item on BCBSIL plans and may carry a different tier.

Novolog vs. Preferred Alternatives on BCBSIL

When BCBSIL places a competing rapid-acting insulin at a lower tier than Novolog, switching to that product can reduce your copay. The three most common alternatives are:

Humalog (insulin lispro). Onset, peak, and duration are clinically interchangeable with Novolog. A Cochrane systematic review of 10 randomized trials (N=2,751) found no significant difference in A1C, hypoglycemia rates, or patient satisfaction between insulin aspart and insulin lispro 10. If BCBSIL prefers Humalog, switching is straightforward for most patients.

Admelog (insulin lispro, Sanofi). An FDA-approved follow-on biologic to Humalog. Admelog often sits at a lower tier because Sanofi offers aggressive rebates. Clinical equivalence to Humalog has been confirmed in the SORELLA studies 11.

Insulin lispro (authorized generic). Eli Lilly's authorized generic of Humalog carries a list price roughly 50% below brand Humalog. Some BCBSIL formularies place it at Tier 1 (generic), producing copays as low as $10 to $25.

The ADA Standards of Care note that "there are no consistent advantages of one rapid-acting insulin analog over another in terms of glycemic control" 1. If your provider specifically prescribes Novolog and your plan prefers a different analog, ask whether the clinical reason warrants a formulary exception or whether a switch is clinically acceptable.

How to Check Your Specific BCBSIL Coverage

Formulary placement is plan-specific. Two BCBSIL members living on the same street may have different Novolog tiers if their employers chose different plan designs. Follow these steps to confirm your coverage:

1. Log into Blue Access for Members (BAM). Manage to the "Pharmacy" or "Prescription Drug Benefits" section and search for "insulin aspart" or "Novolog."
2. Review your Summary of Benefits and Coverage (SBC). This document lists your pharmacy benefit tiers, copay amounts, and deductible requirements.
3. Call BCBSIL member services. The number is on the back of your insurance card. Ask specifically: "Is Novolog on my formulary, what tier is it, and is prior authorization required?"
4. Use the BCBSIL formulary lookup tool. BCBSIL publishes searchable formulary PDFs at its website, organized by plan type (PPO, HMO, Blue Choice).

If Novolog is not covered or is at a non-preferred tier, your prescriber can submit a coverage determination request. BCBSIL must respond within 72 hours for expedited requests and 15 days for standard requests.

Patient Assistance and Copay Programs

Several programs can reduce Novolog costs regardless of your BCBSIL tier:

Novo Nordisk Patient Assistance Program (PAP). Uninsured patients with household income at or below 400% of the federal poverty level may qualify for free Novolog 12. Apply through NovoCare.com.

Novo Nordisk copay card. Commercially insured patients may pay as little as $25 per 30-day Novolog prescription for up to 24 months, subject to annual maximums. This card cannot be used with government insurance (Medicare, Medicaid, Tricare).

BCBSIL mail-order pharmacy. Using the BCBSIL preferred mail-order pharmacy (often Prime Therapeutics or Express Scripts, depending on your plan) for a 90-day supply can reduce your per-unit cost by 10% to 20% compared to retail fill.

Illinois 340B-eligible health centers. Federally qualified health centers (FQHCs) in Illinois participating in the 340B Drug Pricing Program can dispense Novolog at significantly reduced prices, sometimes below $50 per vial 13.

A 2023 analysis in JAMA Internal Medicine found that 14.3% of U.S. adults with diabetes reported rationing insulin due to cost in the prior 12 months 14. These programs exist to prevent exactly that scenario.

Medicare Part D and Novolog Under BCBSIL

BCBSIL administers several Medicare Advantage and Medicare Part D plans in Illinois. Under the Inflation Reduction Act, all Medicare Part D plans, including those administered by BCBSIL, must cap insulin cost-sharing at $35 per month per insulin product 4. This cap applies during all phases of Part D coverage, including the deductible phase and the coverage gap (formerly the "donut hole").

For 2025 and 2026, Medicare Part D also includes a $2,000 annual out-of-pocket maximum on all covered prescription drugs, which provides additional protection for patients using multiple medications alongside Novolog 4.

A 2024 CDC National Diabetes Statistics Report estimated that 37.3 million Americans have diabetes, and approximately 8.4 million use insulin 15. The $35 cap applies to all of them if they have Medicare Part D coverage.

Medicaid Managed Care Under BCBSIL in Illinois

BCBSIL participates in the Illinois Medicaid managed care program. Illinois Medicaid covers all FDA-approved insulins, including Novolog, with minimal or zero cost-sharing for most recipients. The Illinois Department of Healthcare and Family Services (HFS) preferred drug list determines whether Novolog or a competing analog is the default covered product. If Novolog is not the preferred Medicaid product, prescribers can obtain approval through the state's prior approval process by documenting medical necessity.

Under federal Medicaid rules, states must cover all products from manufacturers that participate in the Medicaid Drug Rebate Program, which includes Novo Nordisk 16. A Medicaid denial of Novolog is therefore unusual and typically resolved through a prior approval submission.